# Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)

> **NCT07629206** · NA · RECRUITING · sponsor: **IceCure Medical Ltd.** · enrollment: 400 (estimated)

## Conditions studied

- Low-Risk, Early Stage Breast Cancer

## Interventions

- **DEVICE:** Cryoablation

## Key facts

- **NCT ID:** NCT07629206
- **Lead sponsor:** IceCure Medical Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-17
- **Primary completion:** 2034-07
- **Final completion:** 2034-09
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07629206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07629206, "Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07629206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*